Kardigan raised $400 million in its upsized Nasdaq IPO, pricing at $16 per share at the top of its range, signaling renewed biotech investor appetite.

Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to…

Kardigan Announces Pricing of Upsized Initial Public Offering